Skip to main content

Shaun Goodman, MD, MSc, FRCPC, FACC, FESC, FAHA

Associate Head, Division of Cardiology

Shaun Goodman, MD, MSc, FRCPC, FACC, FESC, FAHA

Associate Head, Division of Cardiology

St. Michael’s Hospital

Professor, Department of Medicine

University of Toronto

Toronto, Ontario

Related Videos

What did ODYSSEY Outcomes and FOURIER teach us about high-risk patients with diabetes and the relative favorability of their responses to LDL-C lowering with PCSK9 inhibitors?

What did ODYSSEY Outcomes and FOURIER teach us about high-risk patients with diabetes and the relative favorability of their responses to LDL-C lowering with PCSK9 inhibitors?

What should the approach be in patients who have had a coronary event with an LDL-C level of 70 mg/dL? Do the outcome studies with PCSK9 inhibitors provide an evidentiary roadmap for this common situation?

What should the approach be in patients who have had a coronary event with an LDL-C level of 70 mg/dL? Do the outcome studies with PCSK9 inhibitors provide an evidentiary roadmap for this common situation?

What have we learned from the ODYSSEY Outcomes pharmacoeconomic analysis that you and Professor Deepak Bhatt reported at the AHA 2018 Meeting? And what are the implications for the clinician-cardiologist who is making the case to payors?

What have we learned from the ODYSSEY Outcomes pharmacoeconomic analysis that you and Professor Deepak Bhatt reported at the AHA 2018 Meeting? And what are the implications for the clinician-cardiologist who is making the case to payors?

How exactly did you and your colleagues model the pharmacoeconomic effectiveness of alirocumab based on the actual results of the ODYSSEY Outcomes Trial?

How exactly did you and your colleagues model the pharmacoeconomic effectiveness of alirocumab based on the actual results of the ODYSSEY Outcomes Trial?

How have the 2016 Canadian Cardiovascular Society Guidelines for LDL-C reduction positioned their recommendations for LDL-C target goals, and how do you anticipate these might change in the future based on the ODYSSEY Outcomes and FOURIER Trials?

How have the 2016 Canadian Cardiovascular Society Guidelines for LDL-C reduction positioned their recommendations for LDL-C target goals, and how do you anticipate these might change in the future based on the ODYSSEY Outcomes and FOURIER Trials?

How do you approach the diabetic patient who also has a constellation of multiple high-risk features, above and beyond the underlay of diabetes? What is the relative and absolute benefit of employing PCSK9 inhibitors in this patient population?

How do you approach the diabetic patient who also has a constellation of multiple high-risk features, above and beyond the underlay of diabetes? What is the relative and absolute benefit of employing PCSK9 inhibitors in this patient population?

What LDL-C target goals should a consulting or treating medical cardiologist recommend for patients with Type 2 diabetes—with a known ACS event vs. diabetes alone as a risk factor?

What LDL-C target goals should a consulting or treating medical cardiologist recommend for patients with Type 2 diabetes—with a known ACS event vs. diabetes alone as a risk factor?

From a medical cardiologist and ACS expert perspective, can you identify which patients should undergo consideration for PCSK9-mediated LDL-C reduction and what risk factors should encourage CV specialists to pursue PCSK9-based therapies?

From a medical cardiologist and ACS expert perspective, can you identify which patients should undergo consideration for PCSK9-mediated LDL-C reduction and what risk factors should encourage CV specialists to pursue PCSK9-based therapies?